Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Didanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Didanosine SCHEMBL16695883 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL16695888 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL3363 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL16695885 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL5021456 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL7904473 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL887093 | 0.95 | ALDH1A1 (0.91) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL284944 | 0.95 | ALDH1A1 (0.91) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL2327408 | 0.92 | ALDH1A1 (0.85) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL7787270 | 0.92 | ALDH1A1 (0.84) | ALDH1A1LMNAALBMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2259787-B1 | IKKI INHIBITOR THERAPIES AND SCREENING METHODS, AND RELATED IKKI DIAGNOSTICS | UNIV MICHIGAN (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2922572-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB Science (FR) | 2015-09-30 | — | — | EP | disclosed |
| EP-2869823-A1 | METHOD OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | Chimerix, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014079709-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014008344-A1 | METHOD OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-8609609-B2 | Peptides and methods of use as therapeutics and screening agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2010166-B1 | ORGANIC DISULFIDE ANTIRETROVIRAL AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2013076586-A2 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENTS | ADVANCED BIOLOGICAL LABORATORIES SA (LU) | 2013-05-30 | — | — | WO | disclosed |
| EP-0708085-B1 | Antiviral ethers of aspartate protease substrate isosteres | NOVARTIS AG (CH) | 2002-07-17 | — | — | EP | disclosed |
| EP-0876336-B1 | AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES | NOVARTIS AG (CH) | 2002-06-05 | — | — | EP | disclosed |
| EP-0915841-B1 | ANILINOPEPTIDE DERIVATIVES | NOVARTIS AG (CH) | 2002-02-27 | — | — | EP | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| WO-2001054717-A1 | VACCINE COMPOSITION, PROCESS AND METHODS | JIRA VIC (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6225345-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME | NOVARTIS AG (CH) | 2001-05-01 | — | — | US | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0877937-A1 | METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS | VIRCO N.V. (BE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997027480-A1 | METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS | VIRCO N.V. (BE) | 1997-07-31 | — | — | WO | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |